American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 127-130 , January 2008

Antibody-Mediated Rejection With a Striking Interstitial Monocyte/Macrophage Infiltration in a Renal Allograft Under FTY720 Treatment

  • Banu Sis, MD

      Affiliations

    • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
    • Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada.
    • Corresponding Author InformationAddress correspondence to Banu Sis, MD, University of Alberta, Department of Medicine, Division of Nephrology & Immunology, #250 Heritage Medical Research Centre, University of Alberta, Edmonton, AB, T6G 2S2, Canada.
    • ,
  • Richard Grynoch, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada.
    • ,
  • Allan G. Murray, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada.
    • ,
  • Patricia Campbell, MD

      Affiliations

    • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
    • Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada.
    • ,
  • Kim Solez, MD

      Affiliations

    • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada

Received 8 April 2007 ,Accepted 15 August 2007.

References 

  1. Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4:1019–1025
  2. Dragun D, Fritsche L, Boehler T, Peters H, Budde K, Neumayer HH. FTY720: Early clinical experience. Transplant Proc. 2004;36(suppl 2S):S544–S548
  3. Kahan BD. FTY720: From bench to bedside. Transplant Proc. 2004;36(suppl 2S):S531–S543
  4. Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci. 2000;21:49–52
  5. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160:5037–5044
  6. Ferguson R. FTY720 immunomodulation: Optimism for improved transplant regimens. Transplant Proc. 2004;36(suppl 2S):S549–S553
  7. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200–205
  8. Xu M, Pirenne J, Antoniou EA, Afford SC, D’Silva M, McMaster P. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transpl Int. 1998;11:288–294
  9. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073–1083
  10. Budde K, Schmouder RL, Nashan B, et al. Pharmacodynamics of single dose of the novel immunosuppressant FTY720 in stable renal patients. Am J Transplant. 2003;3:846–854
  11. Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo controlled, phase I study. Transplantation. 2003;76:1079–1084
  12. Tedesco-Silva H, Kahan B, Mourad G, et al. FTY720 combined with Neoral and corticosteroids is effective and safe in prevention of acute rejection (AR) in renal allograft recipients (interim data). Am J Transplant. 2001;1(suppl 1):S243A;abstr
  13. Tedesco-Silva H, Mourad G, Kahan B, et al. FTY720, a novel immunomodulator—Efficacy and safety results from the first phase 2a study in de novo renal transplantation. Transplantation. 2005;79:1553–1560
  14. Walker R, Ferguson RM, Mulgaonker S, et al. FTY720 with reduced cyclosporine exposure is efficacious in preventing rejection in renal transplantation: 12-Month preliminary results. Nephrol Dial Transplant. 2003;18(suppl 4):S499A;abstr
  15. Salvadori M, Budde K, Charpentier B, et al. FTY720 0124 Study Group FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6:2912–2921
  16. Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. FTY720 Study Group Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation. 2006;82:1689–1697
  17. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria—An addition to the Banff ’97 classification of renal allograft rejection. Am J Transplant. 2003;3:1–7
  18. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723
  19. Jose MD, Ikezumi Y, Van Rooijen N, Atkins RC, Chadban SJ. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation. 2003;76:1015–1022
  20. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003;76:120–129
  21. Shimizu H, Takahashi M, Kaneko T, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation. 2005;111:222–229
  22. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 1998;281:96–99
  23. Mitchison NA. T-Cell-B-cell cooperation. Nat Rev Immunol. 2004;4:308–312

 Originally published online as doi:10.1053/j.ajkd.2007.08.023 on November 30, 2007.

PII: S0272-6386(07)01355-8

doi: 10.1053/j.ajkd.2007.08.023

American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 127-130 , January 2008

Article Tools

* Image Usage & Resolution